





marked the **30th anniversary** e National Coalition for Cancer evorship (NCCS).

From the first organizing meeting in Albuquerque, New Mexico, to the halls of Congress in Washington, D.C., NCCS quickly established itself as a national leader in cancer policy advocacy. We are the oldest survivor-led advocacy organization in the nation, and I am proud and humbled to serve as CEO for an organization with such a critical mission and an influential history. NCCS first established survivorship issues, and continues to be an outspoken leader to improve care for patients and families from the moment of diagnosis.

No one was a more dedicated or effective advocate on these issues than former NCCS CEO Ellen L. Stovall, who sadly and suddenly passed away in January 2016. Her dedication to advocacy and her personal experience with cancer were a source of inspiration at NCCS. Her death further fueled our dedication to transforming cancer care in her memory and improving the experience for millions of survivors and their families. The outpouring of support at her memorial service, where hundreds of people attended to pay their respects and honor her life as a pioneer, was heartening to her family, friends, and colleagues. She continues to be missed and will be always remembered.

Thank you for your continued support of NCCS. I am excited for what 2017 and the next 30 years holds for NCCS as we transform cancer care to be more inclusive of the needs and values of everyone impacted by cancer.

Sincerely,

Shelley Fuld NassoChief Executive Officer

NCCS policy priorities



Care coordination and planning



Care that incorporates patients' goals and values



Affordable, accessible, quality health care



Payment reform



High-quality review to ensure safe and effective cancer drugs reach patients





 Jen's story highlights several areas where NCCS is focused on improving cancer care policy by engaging on Capitol Hill, in federal agencies, and with advocates

Year in Review.

2016 was filled with accomplishments and growth for NCCS. Our capacity to create change in our health care system was made even stronger as we added several individuals to our team:



Lindsay HouffPublic Policy Manager



Kelsey Nepote Advocacy Manager



Brandi Stevenson
Office Manager and
Development Associate



Dan Weber
Director of Communications







Transformi Care.

Photo by: Andrew Ta



01

Launched the Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care

NCCS presented the inaugural Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care to Douglas W. Blayney, MD, FACP. Dr. Blayney is past president of the American Society of Clinical Oncology (ASCO) and worked closely with Ellen for many years to improve the quality of cancer care for survivors. Moving forward, this award will be an annual, nationwide competition to identify a provider or practice that is providing cancer patients and their families with exceptional, coordinated patient-centered care. Dr. Blayney will serve as cochair of an advisory committee to establish the award's criteria and evaluate nominations. For more info, visit StovallAward.org

02

Oncologist-Patient Focus Groups

NCCS held focus groups with oncologists and patients that further illustrated the significant divide in doctor-patient communication and some of the challenges that persist. With both groups, it was clear that attitudes and mindsets differed greatly, further complicating how to tailor strategies to improve communication. Especially with the patients, who ranged from a "doctor knows best" attitude to a "patient takes charge" approach, it was clear a one-size-fits-all approach would not be sufficient. The findings show that work remains to customize approaches to increase effective doctor-patient communication, and highlights areas for further investigation. We published a paper on this research in the October issue of *Evidence-Based Oncology*.

03

Raising Awareness for Survivorship

NCCS also represented cancer survivors on the American Society of Clinical Oncology's Cancer Survivorship Committee, and co-authored a paper in the *Lancet Oncology* entitled, "Defining cancer survivors, their needs, and perspectives on survivorship health care in the USA."





01

Cancer Policy Roundtables

NCCS hosted its 16th year of semi-annual Cancer Policy Roundtable (CPR) "think tank" meetings, convening stakeholders to discuss health care policy improvements. The spring CPR, titled "What Do Cancer Patients Value in Treatment Options, Communications, and Care?", included a panel of cancer survivors discussing what it means to be an empowered patient and how they navigated the cancer care system to obtain the care that matches their goals and values. We also discussed improving doctor-patient communication and including patient values in cancer drug research and development.

The fall CPR, "Post-Election: What's Next for Cancer Policy?", focused on what the results of the 2016 election mean for cancer survivors and health care policy moving forward.

President Obama signs 21st Century Cures Act into law, with \$1.8 billion in funding for the Cancer Moonshot.



02

Quality Measurement

Quality measurement is an important component of reforms to the health care system to deliver patient-centered care that is based on value rather than volume. NCCS served on several important committees of the National Quality Forum that review and approve quality measures. NCCS partnered with the National Committee for Quality Assurance on a project, funded by the Patient-Centered Outcomes Research Institute (PCORI), to evaluate the patient-centered medical home model for oncology. We continue to advocate for improving cancer care through the implementation of the Oncology Care Model by the Center for Medicare and Medicaid Innovation (CMMI).

03

Cancer Moonshot

NCCS participated in a working group that advised the Blue Ribbon Panel as part of Vice President Biden's Cancer Moonshot. NCCS was pleased that one of the Panel's recommendations included supporting symptom management research to minimize the debilitating side effects of cancer treatment.






Impacting Policy.




Promoting Advocacy.

NCCS' Cancer Policy and Advocacy Team (CPAT) Symposium and Hill Day in Washington, D.C., was a tremendous success.

Advocates from across the country attended two days of informative presentations and discussions on cancer policy and advocacy.



We also hosted webinars for CPAT members about timely topics. One was titled, "A Conversation Around Shared Decision-Making and a Patient Revolution—and the Role of the PACT Act," where Victor M. Montori, MD, MSc, discussed shared decision-making and Adriane Casalotti, deputy chief of staff for Congresswoman Lois Capps of California, spoke about the PACT Act. Another webinar NCCS hosted was titled, "Social Media Strategies for Patient Advocates," and shared best practices for various social media platforms to help advocates increase their impact at the local and federal levels.



- Help cancer patients through the difficult process of cancer diagnosis, treatment choices, treatment management, and survivorship care by supplying them with a written plan or roadmap.
- Encourage a shared decision-making process between patients and their cancer care teams.
- Support informed decision-making as treatment choices become increasingly complex.
- Empower the patient with tools to manage care from active treatment through long-term survivorship.



Financials.

Statement of activities and changes in net assets for the year ended December 31, 2016

<u> </u>	2016
REVENUE	
TOTAL REVENUE	\$2,115,706
EXPENSES	
TOTAL EXPENSES	\$2,096,350
CHANGE IN NET ASSETS	\$19,356
NET ASSETS (BEGINNING OF YEAR)	\$870,827
NET ASSETS (END OF YEAR)	\$890,183

The 2016 numbers represented above are preliminary and are subject to change upon audit.




National Coalition for Cancer Survivorship statement of financial position December 31, 2016

	2016
CURRENT ASSETS	
TOTAL CURRENT ASSETS	\$721,366
OTHER ASSETS	
TOTAL OTHER ASSETS	\$541,264
TOTAL ASSETS	\$1,262,630

CURRENT LIABILITIES	
TOTAL CURRENT LIABILITIES	\$372,447
NET ASSETS	
TOTAL NET ASSETS	\$890,183
TOTAL LIABILITIES AND NET ASSETS	\$1,262,630

EXPENSES AT A GLANCE



Board Members.



Lyman (Sandy)
Welton



Samira Beckwith



Barbara Hoffman



Laurie Isenberg



Michael Kappel



Jennifer McGihor



Eleanor Winter



Policy Advisors.

Gregory J. Aune, MD, PhD

University of Texas Health Science Center, San Antonio

Stuart M. Butler, PhD

Brookings Institution

John V. Cox, DO

Parkland Hospital

Bob Erwin

Marti Nelson Cancer Foundation

Scott Gottlieb, MD

American Enterprise Institute

Pamela Haylock, PhD, RN, FAAN

Sul Ross State University

Michael Kolodziej, MD

Flatiron Health

Michael Link, MD

Stanford Cancer Institute

Jennifer Malin, MD

UnitedHealthcare

Mary McCabe, RN, MN

Memorial Sloan-Kettering Cancer Center

Therese M. Mulvey, MD, FASCO

Massachusetts General Hospital

Lee Newcomer, MD

UnitedHealthcare

Kevin C. Oeffinger, MD

Duke Cancer Institute

Ann H. Partridge, MD, MPH

Dana-Farber Cancer Institute

Kavita Patel, MD

Brookings Institution

Derek Raghavan, MD, PhD, FACP, FRACP

Levine Cancer Institute

Jeffrey Scott, MD

Strategic Oncology Consultants

Joshua M. Sharfstein, MD

Johns Hopkins Bloomberg School of Public Health

Thomas Smith, MD

Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University

Jennifer S. Temel, MD

Massachusetts General Hospital

Donors.

PREMIER SPONSOR

Amgen

Bristol-Myers Squibb Company

Eisai, Inc.

Genentech, Inc.

Lilly USA, LLC

Merck

Novartis Pharmaceuticals

Corporation

Pfizer, Inc.

BENEFACTOR SPONSOR

Astellas Pharmaceuticals

Boehringer Ingelheim

Pharmaceuticals Inc.

Jazz Pharmaceuticals, Inc.

Takeda Oncology

PATRON SPONSOR

AbbVie Inc.

Bayer HealthCare LLC

Celgene Corporation

Johnson & Johnson Healthcare

Inc.

Pharmaceutical Research &

Manufacturers of America

SUSTAINING SPONSOR

Biotechnology Industry

Organization

Taiho Oncology, Inc.

SUPPORTING SPONSOR

American Society of Clinical

Oncology

Anthem, Inc.

Helsinn Therapeutics, Inc.

Stubblefield Foundation Inc.

TESARO, Inc

ASSOCIATE SPONSOR

Carolinas Healthcare System

Combined Federal

Campaign

Daniel A. Mica, LLC

David Katz Foundation

Foundation for the Carolinas

Laurie Isenberg and

Joel Roos

Musa Mayer

John Rakoske

Turner & Goss LLP

Eleanor Winter and

Dan Backo

7D Wines

PLATINUM SURVIVORS' CIRCLE

Andrea and Mitchell Becker

iHeartMedia Management

Services, Inc.

Julia H. Rowland, PhD

GOLD SURVIVORS' CIRCLE

American Society for Radiation

Oncology

Samira K. Beckwith

Jane and Jeff Bulman

C. Norman and Karolynn

Coleman

Kite Pharma

Kate Ditzler

Lucinda N. Dudley

Patricia Ganz. MD

Danielle Hatfield

Fitzhugh Mullan, MD and

Irene Dankwa-Mullan, MD

Therese M. Mulvey, MD

Shelley and Michael Nasso

National Committee for Quality

Assurance

National Patient Advocate

Foundation

Lynn Nye

Corinne B. Roberts

Robert Sachs

Leslie Seeman

The John A. Hartford

Foundation, Inc.

The Original Pancake House

Steven C. Thorntol

Susan L. Weiner

SILVER SURVIVORS' CIRCLE

Carolyn Aldige

Carol L. Alter

Barbara J. Barea

Ronald Berenstain

Lezley Blair

Michael G. Cunningham

Debra Curtis

Christin L. Engelhardt

Susan K. Fisher

Maureen Golden

Beverly R. Greenfeig

Miles Haber

Sheila Handel

Richard Hoffstein

Barbara L. Kerxton

Neil Kishter

Stephen Lewis and Alison Wylegala

Alexandra G. Lucy

Liza Lucy

Barbara Maddox

Jennifer Malin

Jennifer McGihon

Tucker L. Melancon

Oncology Nursing Society

Sarah Scholle

Jerome Seidenfeld B100

Catherine D. Sevier

David M. Sevier

Yogendra Sheth

Mark Shostak Ronald Snodgrass

Joseph W. Waz

Cvnthia Young

Robert C. Young

Gary L. Zahrbock

This is the volume of the cancer surv

What most people diagnosed with cance oncologists and their patients understated those treatments and how they should be that population of survivors grows exponent in bringing new therapies forward to treat of consequences of those treatments is part of

vorld of ivorship...

er want is to be cured of the cancer itself; what few and or even want to discuss are the consequences of the managed. This is the world of cancer survivorship, and tially every day, in large part because of the improvement our cancer. Knowing there are short- and long-term the planning for survivorship that must begin at diagnosis.

Ellen L. Stovall

Blog post for National Cancer Survivors Day in 2015



8455 Colesville Road Suite 930 Silver Spring, MD 20910